Skip to main content

Table 1 Baseline characteristics of 155 AS patients according to the three WHO BMI categories

From: Body mass index influences the response to infliximab in ankylosing spondylitis

  Whole AS population
(n= 155)
BMI < 25 kg/m2
(n= 63)
BMI [25-30] kg/m2
(n= 54)
BMI > 30 kg/m2
(n= 38)
Pvalue
Age (years), median [IQR] 43.1 [35.0-51.8] 38.5 [31.6-48.6] 45.0 [35.6-52.6] 45.4 [40.0-50.0] 0.0127
Male gender, n (%) 98 (63.3) 45 (71.4) 36 (66.6) 17 (44.7) 0.0214
HLAB27, n (%) 96 (64.9) 48 (76.2) 28 (57.1) 20 (55.6) 0.0451
Disease duration (years),
median [IQR]
8.0 [3.0-12.0] 8.0 [4.0-12.0] 7.0 [3.0-11.0] 6.0 [3.0-12.0] 0.7640
BASDAI
(0 to -100 mm), median [IQR]
60.0 [47.5-70.0] 60.0 [50.0-73.0] 56.0 [48.0-66.0] 62.0 [34.0-70.0] 0.4782
VAS pain
(0 to 100 mm), median [IQR]
61.0 [50.0-75.0] 65.0 [50.0-80.0] 60.0 [50.0-70.0] 70.0 [49.0-75.0] 0.4598
Use of NSAIDs
(% of maximal dose), mean (SD)
62.2 (45.7) 72.2 (42.9) 53.7 (42.9) 57.4 (46.0) 0.0703
CRP (mg/dl), median [IQR] 10.0 [5.0-24.0] 11.0 [5.0-23.0] 14.0 [5.0-33.0] 7.9 [5.0-16.0] 0.2550
  1. AS, Ankylosing spondylitis; BASDAI; Bath ankylosing spondylitis disease activity index; BMI, body mass index; CRP, C-reactive protein; IQR, interquartile range NSAID, nonsteroidal antiinflammatory drugs; VAS, visual analogue scale.